Amylyx Pharmaceuticals Inc
AMLX7.860USD
+0.145+1.88%
交易中 （美東）報價延遲15分鐘
700.18M總市值
虧損本益比TTM
關於 Amylyx Pharmaceuticals Inc 公司
Amylyx Pharmaceuticals, Inc. 是一家商業階段的生物製藥公司。該公司致力於發現和開發神經退行性疾病的治療方法。該公司專注於其候選產品的開發和商業化：用於治療 Wolfram 綜合徵和進行性核上性麻痹的 AMX0035，以及該公司用於治療肌萎縮側索硬化症 (ALS) 的靶向鈣蛋白酶-2 的反義寡核苷酸 AMX0114。AMX0035 是一種雙未摺疊蛋白反應 (UPR)-Bax 凋亡抑制劑，由 PB 和 TURSO（也稱爲 TUDCA）組成。該公司的 Avexitide 是一種在研的、一流的胰高血糖素樣肽 1 (GLP-1) 受體拮抗劑，已在五項臨牀試驗中針對減肥後低血糖症 (PBH) 進行了評估，並且還針對先天性高胰島素血癥 (HI) 進行了研究，這兩種疾病的特徵都是高胰島素血癥性低血糖。
公司簡介
公司代碼AMLX
公司名稱Amylyx Pharmaceuticals Inc
上市日期Jan 07, 2022
CEOMr. Justin Klee
員工數量123
證券類型Ordinary Share
年結日Jan 07
公司地址43 Thorndike Street
城市CAMBRIDGE
上市交易所NASDAQ Global Select Consolidated
國家United States of America
郵編02141
電話16176820917
網址https://www.amylyx.com/
公司代碼AMLX
上市日期Jan 07, 2022
CEOMr. Justin Klee
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Dr. Camille L. Bedrosian, M.D.
Dr. Camille L. Bedrosian, M.D.
Chief Medical Officer
Chief Medical Officer
194.38K
+40.46%
Dr. Bernhardt (Bernie) Zeiher, M.D.
Dr. Bernhardt (Bernie) Zeiher, M.D.
Independent Director
Independent Director
--
--
Dr. George Mclean Milne, Ph.D.
Dr. George Mclean Milne, Ph.D.
Chair of the Board of Directors
Chair of the Board of Directors
--
--
Ms. Lindsey Allen
Ms. Lindsey Allen
IR Contact Officer
IR Contact Officer
--
--
Mr. Joshua B. Cohen
Mr. Joshua B. Cohen
Co-Chief Executive Officer, Director
Co-Chief Executive Officer, Director
--
--
Mr. Paul Fonteyne
Mr. Paul Fonteyne
Independent Director
Independent Director
--
--
Mr. James M. Frates
Mr. James M. Frates
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Karen M. Firestone
Ms. Karen M. Firestone
Independent Director
Independent Director
--
--
Ms. Daphne E. Quimi, CPA
Ms. Daphne E. Quimi, CPA
Independent Director
Independent Director
--
--
Mr. Justin Klee
Mr. Justin Klee
Co-Chief Executive Officer, Director
Co-Chief Executive Officer, Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Camille L. Bedrosian, M.D.
Dr. Camille L. Bedrosian, M.D.
Chief Medical Officer
Chief Medical Officer
194.38K
+40.46%
Dr. Bernhardt (Bernie) Zeiher, M.D.
Dr. Bernhardt (Bernie) Zeiher, M.D.
Independent Director
Independent Director
--
--
Dr. George Mclean Milne, Ph.D.
Dr. George Mclean Milne, Ph.D.
Chair of the Board of Directors
Chair of the Board of Directors
--
--
Ms. Lindsey Allen
Ms. Lindsey Allen
IR Contact Officer
IR Contact Officer
--
--
Mr. Joshua B. Cohen
Mr. Joshua B. Cohen
Co-Chief Executive Officer, Director
Co-Chief Executive Officer, Director
--
--
Mr. Paul Fonteyne
Mr. Paul Fonteyne
Independent Director
Independent Director
--
--
收入明細
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
暫無數據
地區USD
名稱
營收
佔比
United States
87.37M
0.00%
業務
地區
暫無數據
股東統計
更新時間: 7月25日 週五
更新時間: 7月25日 週五
持股股東
股東類型
持股股東
持股股東
佔比
Perceptive Advisors LLC
8.83%
TCG Crossover Management, LLC
6.67%
Adage Capital Management, L.P.
6.39%
The Vanguard Group, Inc.
5.05%
Klee (Justin B)
3.76%
Other
69.30%
持股股東
持股股東
佔比
Perceptive Advisors LLC
8.83%
TCG Crossover Management, LLC
6.67%
Adage Capital Management, L.P.
6.39%
The Vanguard Group, Inc.
5.05%
Klee (Justin B)
3.76%
Other
69.30%
股東類型
持股股東
佔比
Hedge Fund
37.33%
Investment Advisor
25.77%
Individual Investor
9.53%
Private Equity
9.22%
Investment Advisor/Hedge Fund
6.10%
Research Firm
3.54%
Venture Capital
2.72%
Pension Fund
0.22%
Sovereign Wealth Fund
0.13%
Other
5.44%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
402
86.90M
97.48%
-7.80M
2025Q1
421
95.29M
107.20%
-3.35M
2024Q4
427
70.75M
84.73%
-29.75M
2024Q3
419
63.91M
89.33%
-37.09M
2024Q2
415
63.87M
89.96%
-35.05M
2024Q1
393
69.90M
101.03%
-23.62M
2023Q4
373
76.45M
112.48%
-12.85M
2023Q3
341
74.63M
110.02%
-3.94M
2023Q2
310
76.31M
113.70%
-2.01M
2023Q1
276
73.14M
110.85%
-1.57M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Perceptive Advisors LLC
7.87M
8.83%
+1.10M
+16.24%
Mar 31, 2025
TCG Crossover Management, LLC
5.94M
6.67%
+1.30M
+27.99%
Mar 31, 2025
Adage Capital Management, L.P.
5.70M
6.39%
+5.70M
--
Mar 31, 2025
The Vanguard Group, Inc.
4.12M
4.62%
+1.42M
+52.89%
Mar 31, 2025
Klee (Justin B)
3.36M
3.76%
+235.72K
+7.56%
Apr 11, 2025
Cohen (Joshua Barry)
3.36M
3.76%
+299.42K
+9.80%
Apr 11, 2025
Millennium Management LLC
3.08M
3.46%
+2.49M
+418.62%
Mar 31, 2025
Nantahala Capital Management, LLC
2.93M
3.29%
+1.48M
+102.07%
Mar 31, 2025
Citadel Advisors LLC
2.76M
3.09%
+787.07K
+39.94%
Mar 31, 2025
Saturn V Capital Management LP
2.43M
2.72%
+1.54M
+172.92%
Mar 31, 2025
查看更多
持股ETF
更新時間: 8月2日 週六
更新時間: 8月2日 週六
機構名稱
佔比
iShares Neuroscience and Healthcare ETF
1.03%
Invesco Dorsey Wright SmallCap Momentum ETF
0.44%
Federated Hermes MDT Small Cap Core ETF
0.22%
iShares Micro-Cap ETF
0.1%
Invesco Nasdaq Biotechnology ETF
0.06%
ProShares Ultra Nasdaq Biotechnology
0.06%
Avantis US Small Cap Equity ETF
0.05%
Invesco Russell 2000 Dynamic Multifactor ETF
0.04%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.04%
iShares Biotechnology ETF
0.04%
查看更多
iShares Neuroscience and Healthcare ETF
佔比1.03%
Invesco Dorsey Wright SmallCap Momentum ETF
佔比0.44%
Federated Hermes MDT Small Cap Core ETF
佔比0.22%
iShares Micro-Cap ETF
佔比0.1%
Invesco Nasdaq Biotechnology ETF
佔比0.06%
ProShares Ultra Nasdaq Biotechnology
佔比0.06%
Avantis US Small Cap Equity ETF
佔比0.05%
Invesco Russell 2000 Dynamic Multifactor ETF
佔比0.04%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
佔比0.04%
iShares Biotechnology ETF
佔比0.04%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
